Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results
Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results
复制标题
DOI：
10.1111/j.1755-3768.2010.02046.x
复制
发表时间：
2011-03-01
影响因子：
3.4
通讯作者：
Bodaghi, Bahram
中科院分区：
文献类型：
--
作者：
Julian, Karina;Terrada, Celine;Bodaghi, Bahram
目的：报告长期的结果，玻璃体内（IVT）贝伐单抗作为第一个局部治疗脉络膜新生血管（CNV）继发于uveitis.Methods：文件的患者接受1.25 mg/0.05 ml贝伐单抗作为主要的局部治疗CNV进行了回顾性分析。主要结果是最佳矫正视力（BCVA）和中央凹厚度（CFT）的变化，治疗相关的不良事件，以及注射次数和频率。7例诊断为多灶性脉络膜炎和全葡萄膜炎，2例诊断为弥漫性脉络膜炎，6例诊断为匍匐性脉络膜炎、交感性眼炎、Vogt-Koyanagi-Harada综合征、点状内脉络膜病变、结核和特发性炎症。13只眼为中心凹下新生血管，2只眼为乳头周围新生血管。在所有病例中，眼内炎症在注射时得到严格控制。BCVA从logMar 0.53提高到logMar 0.29者12眼（80%），CFT从239.06 μ m下降到195.2 μ m者13眼（87%）。12只眼睛接受了一次以上的注射;该组的平均数量为4.25（2-8），频率为每12.97周1次。没有与贝伐单抗或手术相关的不良事件。中位随访时间为17.6个月（8-25）。结论：贝伐单抗治疗炎症性CNV的首选IVT在炎症控制下的眼睛中表现出BCVA和CFT的短暂改善。在大多数情况下需要重新注射。进一步的工作应总结与重复注射相关的安全性。
Purpose: To report long-term results of intravitreal (IVT) bevacizumab as first local treatment for choroidal neovascularization (CNV) secondary to uveitis.Methods: Files of patients receiving 1.25 mg/0.05 ml bevacizumab as primary local treatment for CNV were retrospectively reviewed. Main outcomes were change in best-corrected visual acuity (BCVA) and central foveolar thickness (CFT), treatment-related adverse events, and number and frequency of injections.Results: Fifteen eyes from fifteen patients were included. Multifocal choroiditis and panuveitis were the diagnosis in seven, ampiginous choroiditis in two, and for six remaining, serpiginous choroiditis, sympathetic ophthalmia, Vogt-Koyanagi-Harada syndrome, punctuate inner choroidopathy, tuberculosis and idiopathic inflammation. In 13 eyes, neovascularization was subfoveal, and peripapillary in two. Intraocular inflammation was strictly controlled in all cases by the time of injections. BCVA improved from logMar 0.53 to logMar 0.29 in 12 eyes (80%), while CFT decreased from 239.06 to 195.2 mu m in 13 (87%). Twelve eyes received more than one injection; mean number in this group was 4.25 (2-8), and frequency 1 every 12.97 weeks. There were no adverse events related to bevacizumab or the procedure. Median follow-up was 17.6 months (8-25).Conclusions: First-intention IVT bevacizumab for inflammatory CNV showed transient improvement in BCVA and CFT, in eyes under controlled inflammation. Reinjection was needed in most cases. Further work should conclude about safety related to repeated injections.